Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters-Reference-Cited by-同舟云学术

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters

Published:2021-04-09 Issue:4 Volume:14 Page:1535-1542
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Shoaf Susan E.¹,Bricmont Patricia²,Repella Gordon Jennifer²

Affiliation:

1. Quantitative Pharmacology Otsuka Pharmaceutical Development & Commercialization, Inc. Rockville Maryland USA

2. Global Clinical Management Otsuka Pharmaceutical Development & Commercialization, Inc Rockville Maryland USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13017

Reference23 articles.

1. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

2. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

3. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

4. Australian Government Dept. of Health Therapeutic Goods Administration.Australian Public Assessment Report for Tolvaptan.https://www.tga.gov.au/auspar/auspar‐tolvaptan‐0(2018). Accessed January 20 2021.

5. Design and evaluation of solid dispersion based tolvaptan immediate release tablets;Magar DD;Indo Am J Pharm Res,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Analysis and <i>in Vitro</i> Correlation of BCRP-Mediated Drug–Drug Interaction in the Gastrointestinal Tract;Biological and Pharmaceutical Bulletin;2024-04-01

2. Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis;Frontiers in Pharmacology;2024-01-26

3. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease;Advances in Kidney Disease and Health;2023-05

4. Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures;Clinical Pharmacology & Therapeutics;2022-08-10